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BACKGROUND: The family of polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) is responsible for the altered glycosylation in
cancer. The purpose of our study was to investigate the clinical significance of two isoforms, GalNAc-T6 and -T3, and their
correlation with the prognosis of pancreatic cancer.
METHODS: Immunohistochemistry was used to analyse GalNAc-T6 and -T3 expressions in 70 clinicopathologically characterised
pancreatic cancer cases.
RESULTS: Positive expressions of GalNAc-T6 and -T3 were immunohistochemically identified in 51% (36 of 70) and in 77% (54 of 70)
of patients, respectively. A close relationship was noted between GalNAc-T6 positive expression and pathological well/moderate
differentiated type (P¼0.001), small tumour size (P¼0.044), absence of vascular invasion (P¼0.009), and low stage of the American
Joint Committee on Cancer systems (P¼0.043). The expression of GalNAc-T3 significantly correlated with good differentiation
(P¼0.001), but not with other clinicopathologic features. Furthermore, univariate and multivariate analyses revealed that GalNAc-T6
expression was an independent prognosis indicator for the disease, whereas GalNAc-T3 expression had no impact on clinical
outcome, even though 33 of 36 GalNAc-T6-positive cases also had a positive expression of GalNAc-T3 (P¼0.001, r¼0.356).
CONCLUSION: Both GalNAc-T6 and -T3 expressions correlated significantly with tumour differentiation, whereas only GalNAc-T6
expression predicted prognosis in pancreatic cancer.
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Pancreatic cancer is responsible for B227000 deaths per year in
the world (Parkin et al, 2005). The 5-year overall survival rate for
all patients diagnosed with pancreatic cancer is o4%. At present,
surgical resection offers the only chance of cure, whereas long-
term survival is rare, with the overall 5-year survival rates ranging
from 10% to 25% (Cleary et al, 2004; Katz et al, 2008). Various
clinicopathologic features, such as tumour size, and vascular
involvement in resectable tumours, or initial patient performance
status and the absence of distant metastasis in unresectable
tumours, have been proposed as prognostic indicators, although
the results remain inconsistent and inconclusive to date. The
clinical importance of biological markers is also under evaluation.
For example, most famously, initial serum levels of carbohydrate
antigen (CA) 19-9, and more recently, Mucin-4, have been shown
to be independent prognosis indicators of pancreatic cancer
(Saitou et al, 2005; Berger et al, 2008). All these factors are useful
guides in standardised clinical management and in establishing an
individualised treatment plan for a patient.
Carbohydrate antigen 19-9 and mucins belong to cell-surface
CAs, which comprise various categories of tumour markers and
are essential in monitoring cell growth and the invasive and
metastatic status of solid tumours. In mammals, the most common
forms of CAs are the mucin-type O-glycans, which may constitute
up to 80% of them (Bresalier, 1994; Brockhausen, 1999; Hollings-
worth and Swanson, 2004; Nagata et al, 2007). The aberrant
glycosylation of mucin-type O-glycans is thought to be associated
with the functional alteration of cancer cells, including their
antigenic and adhesive properties, as well as their potential for
invasion and metastasis (Brockhausen, 2006). The enzymes
responsible for glycosylation of CA – the glycosyltransferases
and glycosidases – thus gain more and more attention (Ohtsubo
and Marth, 2006). Here, we focus on the family of polypeptide
N-acetylgalactosaminyltransferases (GalNAc-Ts) which catalyses
the transfer of N-acetyl-a-D-galactosamine:polypeptide (GalNAc)
from the sugar donor uridine diphosphate (UDP)-GalNAc to the
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sserine and threonine residues of glycoproteins to synthesise the
sugar chains which catalyse the initial step in the synthesis of
mucin-type O-glycans (Marth, 1996).
Despite this seemingly simple function, the GalNAc-Ts form a
big family which includes at least 15 distinct members and as many
as 24 human isozymes. They are localised differentially within
cellular compartments, display tissue-specific expression, and have
different, although partly overlapping, kinetic properties and
acceptor substrate specificities (Ten Hagen et al, 2003). Aberrant
expression of the GalNAc-T isoforms results in aberrant
O-glycosylation and participates in the progression of cancer
(Hollingsworth and Swanson, 2004). According to the previous
literature, GalNAc-T1 was considered to decrease ovarian cancer
risk (Phelan et al, 2010), and the higher expression levels of
GalNAc-T14 correlated with lower histological grade in breast
invasive ductal carcinoma and tumour progression (Wu et al,
2010). The most extensively studied GalNAc-T was GalNAc-T3,
which was proved by our group and others to be expressed in
adenocarcinoma cell lines, but not in other carcinoma cell lines
(Sutherlin et al, 1997; Nomoto et al, 1999). Recent reports showed
that the expression of GalNAc-T3 was a useful indicator of
prognosis in patients with colorectal, gastric, and lung cancer
(Shibao et al, 2002; Onitsuka et al, 2003; Gu et al, 2004). GalNAc-
T6 exhibited a high sequence similarity to GalNAc-T3 in the
coding region and shared similar kinetic properties and acceptor
substrate specificities which are distinct from the other GalNAc-Ts
(Bennett et al, 1999). The expression of GalNAc-T6 has been
reported in most ductal breast carcinomas showing a significant
correlation with T1 stage (Berois et al, 2006), whereas in gastric
carcinomas it is significantly associated with the presence of
vascular invasion (VI) (Gomes et al, 2009). GalNAc-T6 thus could
be considered as an intriguing marker of glycosylation modifica-
tions in cancer. To date, however, no study has assessed
GalNAc-T6 expression and its correlation with GalNAc-T3 in
pancreatic cancer.
In this study, we evaluated the expressions of GalNAc-T6 and
-T3 in pancreatic cancer specimens and their correlation with the
clinicopathologic features of the patients. The results indicated
that GalNAc-T6 and -T3 were highly expressed in half of human
pancreatic cancer cases, all of which were well to moderately
differentiated type, while no or very weak staining was observed
in normal pancreas ductal epithelium or poorly differentiated
cancer. Furthermore, positive expression of GalNAc-T6, but not
GalNAc-T3, is associated with good clinical prognosis of patients.
PATIENTS AND METHODS
Patient information, tumour specimens, and blood
samples
The use of specimens from human subjects was approved by the
Ethics Committee of the University of Occupational and Environ-
mental Health (UOEH) Medical Center. Pathology reports were
reviewed to identify patients who had undergone pancreaticoduo-
denectomy or distal pancreatectomy for pancreatic cancer between
1994 and June 2009 at the hospital of UOEH. Two patients who had
suffered perioperative deaths, defined as death during the patient’s
initial hospitalisation or within 30 days of surgery, were excluded.
A total of 70 patients with available follow-up data comprised the
cohort of this retrospective study. Three pathologists examined all
the resected specimens to confirm the histopathologic features.
The tumour node metastasis system of the American Joint
Committee on Cancer (AJCC) 6th edition was used for staging.
Clinical information was gathered from the patients’ records, and
the survival duration was set as the period from the date of surgery
to death or the most recent clinic visit. Formalin-fixed, paraffin-
embedded tissue blocks were obtained from our department of
pathology. Serum CA19-9 and carcinoembryonic antigen (CEA)
levels were measured at the time of final diagnosis. Normal human
tissue was obtained from non-tumour portions of the surgically
resected specimens.
Preparation of antibody against GalNAc-Ts
Polyclonal antibody against GalNAc-T6 was raised by multiple
immunisations of New Zealand white rabbits with synthetic
peptides. The sequence of the synthetic peptide was GFYT-
PAELKPFWERPPQDP. The specificity of antibody was confirmed
by western blotting and immunohistochemistry with peptide
competition. Anti-GalNAc-T3 polyclonal antibody was generated
in the same way as described previously (Nomoto et al, 1999).
Immunohistochemistry of tissue samples
Immunohistochemical staining was performed by the antibody-
linked dextran polymer method (EnVision; Dako Cytomation,
Inc., Carpinteria, CA, USA). Deparaffinised and rehydrated
5mm sections were incubated in 3% H2O2 for 10min to block
endogenous peroxidase activity. The sections were then rinsed and
incubated with rabbit polyclonal GalNAc-T6 or -T3 antibody for
30min. The second antibody-peroxidase-linked polymers were
then applied, and the sections were incubated with a solution
consisting of 20mg of 3.30-diaminobenzidine tetrahydrochloride,
65mg of sodium azide, and 20ml of 30% H2O2 in 100ml of Tris-
HCl (50mM, pH 7.6). After having been counterstained with
Meyer’s haematoxylin, the sections were observed under a light
microscope. For immunohistochemistry of the neoplastic tissue,
positive areas comprising o10% of the neoplasms were con-
sidered as negative staining. Positive areas that were equal to or
410% were defined as positive staining and were graded into
three categories: weak, positive area of 11–30%; moderate,
31–80%; and strong, 480% positive area.
Cell cultures
Human pancreatic invasive ductal carcinoma cell lines PANC1
(American Type Culture Collection) and PK1 (a kind gift from the
Institute of Development, Aging and Cancer, Tohoku University,
Japan) were maintained in a DMEM medium containing 10% fetal
calf serum (GIBCO BRL, Rockville, MD, USA) at 371Ci na n
atmosphere of 95% air and 5% CO2.
Immunofluorescence of pancreatic cancer cell lines PANC1
and PK1
The pancreatic cancer cell lines PANC1 and PK1 were cultured on
coverslips, fixed with 95% acetone for 5min, and allowed to air
dry. The cells were then incubated with anti-GalNAc-T6 antibodies
for 1h at room temperature (RT), washed with PBS, and reacted
with fluorescein isothiocyanate-conjugated goat anti-rabbit IgG for
1h at RT. After having been washed with PBS, the specimens were
observed under a Nikon ECLIPSE E600 inverted fluorescence
microscope (Nikon, Tokyo, Japan).
Cell fractionation and western blotting
The cells were washed and lysed with RIPA buffer. For nuclear and
cytoplasmic fractions, the cells were scraped in 100ml ice-cold PBS
and centrifuged at 500g for 5min. The cell pellet was resuspended
in 100ml Buffer A (50mM NaCl, 10mM HEPES pH 8.0, 500mM
sucrose, 1mM EDTA, 0.2% Triton X-100, freshly added protease
inhibitors and 7mM 2-mercaptoethanol), vortexed at high speed
for 45s and centrifuged at 2000g for 2min at 41C. The resulting
supernatant was used as a cytoplasmic extract. The pellet was
resuspended in 100ml Buffer B (Buffer A with 25% glycerol and
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The pellet was dissolved in 50ml Buffer B, incubated on ice for
30min with intermittent high speed vortexing and spun down at
11000g for 15min at 41C. The supernatant was diluted to 100ml
with PBS and used as a nuclear extract. Equal amounts of samples
were analysed on an SDS–PAGE gel and then were transferred
onto a nitrocellulose membrane. The membranes were incubated
with the primary antibody and visualised with a secondary
antibody coupled to horseradish peroxidase (Cell Signaling
Technology, Beverly, MA, USA) and SuperSignal West Pico
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). The
b a n d so nt h ew e s t e r nb l o t sw e r ea n a l y s ed densitometrically using Scion
Image software (version 4.0.2; Scion Corp., Frederick, MD, USA).
Statistical analysis
Spearman’s correlation test was used to assess the relation-
ships between variables. Survival curves were plotted by the
K a p l a n–M e i e rm e t h o da n dc o m p a r e dw i t ht h el o g - r a n kt e s t .H a z a r d
ratios and 95% confidence intervals (95% CIs) were estimated
using univariate or multivariate Cox proportional-hazard models. All
statistical tests were two-tailed, with Po0.05 considered significant.
SPSS statistical software (SPSS for Windows, version 16.0.0 (SPSS,
Chicago, IL, USA)) was used for the above statistical analyses.
RESULTS
Patient characteristics
As shown in Table 1, the cohort included 70 patients (40 men and
30 women) with clinicopathologic features representative of
pancreatic cancer. The average age at surgery was 67 years. The
median tumour size was 3.5cm with a range from 1.0 to 7.4cm.
More than half of the patients (62.9%) had lymph node metastasis
at diagnosis, and most of the tumours were graded as well to
Table 1 Correlation between GalNAc-T3 or -T6 expression and clinicopathologic variables
Total GalNAc-T3 positive, n (%) GalNAc-T6 positive n (%)
Variables n (%) Positive, n¼54 P Positive, n¼36 P
Age, years 0.331 0.934
p60 17 (24.3) 14 (82.4) 7 (41.2)
460 53 (75.7) 40 (75.5) 29 (54.7)
Sex 0.751 0.842
Male 40 (57.1) 32 (80.0) 22 (55.0)
Female 30 (42.9) 22 (73.3) 14 (46.7)
Tumour differentiation 0.001 0.001
Well, moderately 61 (87.1) 51 (83.6) 36 (59.0)
Poorly 9 (12.9) 3 (33.3) 0 (0.0)
Tumour size, pathologic
a 0.751 0.044
p3.5cm 30 (58.8) 24 (80.0) 21 (70.0)
43.5cm 21 (41.2) 16 (57.1) 9 (42.9)
N classification 0.085 0.760
Negative 26 (37.1) 23 (88.5) 14 (53.8)
Positive 44 (62.9) 31 (70.5) 22 (50.0)
Stage (AJCC) 0.679 0.043
I–II 51 (72.9) 40 (78.4) 30 (58.8)
III–IV 19 (27.1) 14 (73.7) 6 (31.6)
Margin status 0.607 0.161
Negative 39 (55.7) 31 (79.5) 23 (59.0)
Positive 31 (44.3) 23 (74.2) 13 (41.9)
Lymphatic invasion 0.269 0.954
Absent 4 (5.7) 4 (100.0) 2 (50.0)
Present 66 (94.3) 50 (75.8) 34 (51.5)
Vascular invasion 0.173 0.009
Absent 18 (25.7) 16 (88.9) 14 (77.8)
Present 52 (74.3) 38 (73.1) 22 (42.3)
Perineural invasion 0.676 0.066
Absent 3 (4.3) 2 (66.7) 0 (0.0)
Present 67 (95.7) 52 (77.6) 36 (100.0)
GalNAc-T3 expression — 0.002
Negative 16 (22.9) — 3 (18.6)
Positive 44 (77.1) — 33 (75.0)
GalNAc-T6 expression 0.002 —
Negative 34 (48.6) 21 (61.8) —
Positive 36 (51.4) 33 (91.7) —
Abbreviation: AJCC¼American Joint Committee on Cancer.
aOn 51 resectable tumours.
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smoderately differentiated type. Based on the AJCC criteria, the
majority of the patients had stage II disease. Follow-up was
available for all 70 patients, ranging from 3.1 to 70.0 months, with
a median of 14.1 months. The median overall postoperative
survival duration was 15.9 months, with 1- and 5-year actuarial
survival rates of 58% and 6%, respectively. The records of serum
CA19-9 and CEA levels were available for 59 and 60 cases in the
cohort, respectively. Supplementary Table 1 displays each patient’s
information in detail.
Expression of GalNAc-Ts in normal tissue and pancreatic
cancer specimens
The specificity of the GalNAc-T6 polyclonal antibody was tested
by immunohistochemistry and western blotting. After incuba-
tion of this antibody with the excess of synthesised peptides of
GalNAc-T6, the positive immunostaining was completely abol-
ished (Figure 1). Immunohistochemically, GalNAc-T3 and -T6
showed only cytoplasmic expressions (Figure 2). The expression of
GalNAc-T3 was present in most of the normal ductal epithelium
samples (Figure 2A), whereas GalNAc-T6 expression was rare or
very weakly detectable (Figure 2B). The expression of GalNAc-T3
was present in 54 of 70 (77%) pancreatic adenocarcinoma
specimens: 38%, weak; 23%, moderate; and 16%, strong,
respectively. The expression of GalNAc-T6 was present in 36 of
70 (51%) specimens: 34%, weak; 13%, moderate; and 4%, strong,
respectively. When GalNAc-Ts expression was dichotomised into
groups of either positive (weak to strong staining) or negative, the
GalNAc-T3/-T6 immunoprofile was 19%, ( )/( ); 30%, (þ)/( );
4%, ( )/(þ); and 47%, (þ)/(þ), respectively.
Association of GalNAc-Ts expression with
clinicopathologic variables
To identify the association of GalNAc-Ts expression (GalNAc-Ts
negative vs positive) with the clinical and pathological variables of
the cohort, the variables were dichotomised as shown in Table 1.
There were no significant differences between the patients with
GalNAc-T3 negative and positive tumour expressions regarding
age, gender, tumour location, size, lymph node involvement,
disease stage, margin status, lymphatic invasion, VI, perineural
invasion or serum CA19-9 or CEA level (P40.05), whereas
GalNAc-T3 staining status significantly affected tumour differ-
entiation (P¼0.001; Figures 2C, E, and G). The rate of well to
moderately differentiated tumours in the GalNAc-T3-negative
group was 10 out of 16 (62.5%), but 51 out of 54 (94.4%) in the
GalNAc-T3-positive group. These data were consistent with the
results of a previous study using the same antibody as ours
(Yamamoto et al, 2004). Positive GalNAc-T6 staining also
correlated significantly with well to moderately differentiated type
(P¼0.001; Figures 2D, F, and H). Moreover, it was associated with
early disease stage and absence of VI (P¼0.043 and 0.009,
respectively) in all the tumours and with decreasing tumour size in
the resectable tumours (P¼0.044). Thirty out of thirty-six cases
(83.3%) in the GalNAc-T6-positive group were classified into stage
I/II of the AJCC TNM classification, compared with 21 out of 34
(61.8%) in the GalNAc-T6-negative group.
The 5-year overall survival rate of the cohort was 6%. In a
Kaplan–Meier analysis (Figure 3), GalNAc-T3 expression showed
no prognostic significance in overall survival. In contrast, patients
with GalNAc-T6-positive expression had significantly longer
overall postoperative survival (median, 21.8 months) compared
with those who had GalNAc-T6-negative expression (median, 9.3
months; P¼0.014). For the patients with GalNAc-T6-positive
tumours, an increasing degree of GalNAc-T6 expression was not
associated with better clinicopathologic features or longer survival
(data not shown).
We also evaluated survival rates for GalNAc-T6 status year by
year (Supplementary Table 2). In patients with GalNAc-T6-positive
IHC
Peptide (–) Peptide (+)
71 kDa
43 kDa
GalNAc-T6
WB
-Actin
Figure 1 Immunohistochemical and western blotting analyses of
GalNAc-T6 expressions in well-differentiated pancreatic cancer sample
( 200) and PANC1 cell line after incubation of an anti-GalNAc-T6
polyclonal antibody with or without synthesised peptides of
GalNAc-T6. IHC, immunohistochemistry; WB, western blotting. Bar,
100mm. GalNAc-T6 expression is completely abolished with peptide.
GalNAc-T6 GalNAc-T3
Normal
Well
Moderately
Poorly
Figure 2 Immunohistochemical analysis of GalNAc-T3 (1:3000 dilution)
and GalNAc-T6 (1:1000 dilution) in human pancreatic cancers and normal
ductal specimens ( 100; inset,  400). Bar, 100mm. Normal pancreatic
duct was positive for GalNAc-T3 (A), but negative for GalNAc-T6 (B).
Well and moderately differentiated pancreatic cancers stain positively with
GalNAc-T3 (C and E) and GalNAc-T6 (D and F), respectively. However,
poorly differentiated cancer shows negative staining with both GalNAc-T3
(G) and GalNAc-T6 (H).
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sexpression, the 1- and 2-year survival rates were 80.6% and 41.7%,
respectively. However, for patients without GalNAc-T6 expression,
the survival rates were much less; the rates were 35.3% and 31.4%
(P¼0.0003 and 0.006, respectively). Positive expression of
GalNAc-T6 also showed a significant but modest survival
advantage compared with the 3-, 4-, and 5-year survival rates
(P¼0.028, 0.048, and 0.035, respectively).
GalNAc-T6 represents an independent prognostic indicator
in pancreatic cancer
To assess whether GalNAc-T6 expression was an independent
predictor of overall postoperative survival, a Cox proportional-
hazards model was created in a forward manner including only the
covariates that had a statistically significant correlation (inclusion
threshold, Po0.05) with overall survival (Table 2). Univariate
analysis demonstrated that poor tumour differentiation, advanced
stage and GalNAc-T6-negative status were significant predictors of
poorer survival (P¼0.003, o0.001, and 0.014, respectively).
Margin status had no significant impact on patient survival in
our relatively small cohort (P¼0.124).
Furthermore, multivariate analysis showed that, after correction
for confounding variables, GalNAc-T6 expression remained an
independent prognostic indicator of overall survival (P¼0.024).
Analysis of GalNAc-T6 expression in human pancreatic
cancer cell lines
The immunofluorescence staining of the pancreatic adenocarci-
noma cell lines (PANC1 and PK1) showed a marked expression of
GalNAc-T6 in the cytoplasm in a perinuclear manner (Figure 4).
Western blotting analysis showed GalNAc-T6 expression in the
cytoplasm, whereas very weak nuclear expression was detectable in
both cell lines (Figure 4). Additionally, the expression levels of
GlaNAc-T6 in PANC1 were significantly higher than those in the
PK1 cell line by both methods.
DISCUSSION
Prior studies revealed that GalNAc-T6 expression was detected in a
few kinds of malignancies, and breast cancer was the most studied
type in this field. Interestingly, one group showed that GalNAc-T6
was expressed in most ductal carcinoma in situ and was
significantly associated with the T1 stage rather than higher stage
tumours (Berois et al, 2006). Other studies showed that GalNac-T6
mRNA positively correlated with bone marrow metastasis (Freire
et al, 2006), and knockdown of GalNAc-T6 suppressed the growth
of breast cancer cells (Park et al, 2010). These conflicting results
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Figure 3 Kaplan–Meier curves of overall survival durations in patients
with pancreatic cancer after surgery according to GalNAc-T3 (A) and
GalNAc-T6 (B). Pancreatic cancer patients have similar survival regardless
of GalNAc-T3 expression level (P¼0.956), however, patients with positive
GalNAc-T6 expression have significantly longer survivals than those with
negative GalNAc-T6 expression (P¼0.014).
Table 2 Univariate and multivariate analyses of survival in 70 patients with pancreatic cancer according to clinicopathologic variables and GalNAc-T3
or -T6 expression
Univariate Multivariate
Risk factors Hazard 95% CI P Hazard 95% CI P
GalNAc-T3 expression 0.96 0.51–1.78 0.892
GalNAc-T6 expression 0.52 0.30–0.88 0.014 0.53 0.31–0.92 0.024
Poor differentiation 3.22 1.48–7.00 0.003
Tumour in head of pancreas 0.91 0.53–1.58 0.743
Increasing tumour size 1.86 0.87–3.95 0.109
Presence of LN metastasis 1.46 0.85–2.53 0.175
Advanced stage (III/IV) 3.97 2.10–7.50 o0.001 3.65 1.86–7.16 o0.001
Positive tumour margin 1.49 0.89–2.51 0.132
Presence of LI 1.62 0.90–2.88 0.103
Presence of VI 1.27 0.73–2.20 0.400
Presence of PNI 1.25 0.69–2.26 0.463
Highly serum CA19-9 level 1.60 0.86–2.99 0.137
Highly serum CEA level 1.44 0.71–2.93 0.318
Abbreviations: CI¼confidence interval; LN¼lymph node; LI¼lymphatic invasion; VI¼vascular invasion; PNI¼perineural invasion; CA19-9¼carbohydrate antigen 19-9;
CEA¼carcinoembryonic antigen.
PANC1
IF
C
PANC1 PK1
C N
WB 71 kDa
N
PK1
Figure 4 Immunofluorescent and western blotting analyses of
GalNAc-T6 in pancreatic cancer cell lines PANC1 and PK1. IF,
immunofluorescence. WB, western blotting. The cytoplasmic expression
levels of GalNAc-T6 are significantly higher in primary cancer cell line
PANC1 than those in metastatic cancer cell line PK1 with both methods.
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sare probably due to the heterogeneity of breast cancer, which can
be supported by the fact that distinctive chemotherapy drugs
showed good efficacy on it. By contrast, pancreatic cancer has been
supposed to be a relatively homogeneous cancer with a low
frequency of either molecular or histological variants (Niederhuber
et al, 1995) and would be a better model to demonstrate the
function of GalNAc-T6 in malignancies. Thus, we examined the
clinical relevance of GalNAc-T6 expression in pancreatic cancer.
Expression of GalNAc-T6 was observed in half of pancreatic cancer
specimens, associated closely with well to moderately differen-
tiated type (Po0.001), VI (P¼0.009), early AJCC stage (P¼0.043),
as well as small tumour size in resectable cases (P¼0.044). In both
univariate and multivariate analyses, a positive GalNAc-T6 status
predicted improved overall survival. To our knowledge, this is the
first study to reveal that GalNAc-T6 was an independent
prognostic indicator in patients with pancreatic cancer.
Further analysis of the correlation between GalNAc-T6-positive
expression and better 1-year or 2-year overall survival (P¼0.0003
and 0.006, respectively; Supplementary Table 2) indicated that
positive GalNAc-T6 expression significantly predicted a survival
advantage, especially in the early phase after resection, very similar
to postoperative serum CA19-9 (Berger et al, 2008). Thus, negative
GalNAc-T6 status recommended more aggressive treatment.
Because GalNAc-Ts are in external secretions such as colostrum,
based on the previous literature (Hagen et al, 1993; Bennett et al,
1996; Kitazume et al, 2001), it is very likely that GalNAc-T6 could
be secreted to body fluids too. Therefore, GalNAc-T6 is considered
as a useful candidate for surveillance because it is well known that
480% postoperative relapse (local or distant) occurs within the
first 2 years (Stathis and Moore, 2010).
Additionally, the hypothesis that GalNAc-T6 could be a good
indicator of local aggression and metastasis in pancreatic cancer is
supported by our result that GalNAc-T6 was negatively associated
with VI (P¼0.009, r¼ 0.181). Not only that, but the primary
pancreatic cancer cell line (PANC1) demonstrated, by western
blotting and immunocytochemistry methods, a significantly higher
expression of GalNAc-T6 (Figure 4) than that of PK1 derived from
liver metastasis (Kobari et al, 1984; Motomura et al, 2000),
which was considered as a more aggressive subtype. These results
were consistent with the data of Bennett et al (1999) in which
northern blotting analysis showed that GalNAc-T6 mRNA could
only be detected in one primary cancer cell line (miaPaca2), but
not in other metastatic cancer cell lines such as ASPC1 and
COLO357. Very similarly, our preliminary data showed a relatively
higher expression of GalNAc-T6 in primary colon cancer
specimens than that in asynchronous liver metastatic specimens
(data not shown).
The molecular mechanism to explain this tight relationship
between GalNAc-T6 status and local invasion or metastasis
remains to be elucidated. However, recent studies focusing on
the modulation of GalNAc-Ts to cell adhesion function, as well as
the degradation of connective tissue, provide some useful clues.
Several GalNAc-Ts were shown to affect leukocyte adhesion
through modulating E- and P-selectin counter receptors (Lowe,
2003; Tenno et al, 2007); polypeptide GalNAc-T3, in Drosophila,
was found to regulate integrins and to promote cell adhesion
(Zhang et al, 2008, 2010); and GalNAc-T3 was found to modu-
late the activities of metalloproteinases (Chefetz et al, 2009).
GalNAc-T6 was also found to regulate the cell adhesion molecular
E-cadherin and b-catenin in breast cancer (Park et al, 2010).
Therefore, it is reasonable to hypothesise that GalNAc-T6 can
suppress invasion and metastasis by impacting cell–cell adhesion
and cell–stromal interaction in pancreatic cancer, and we attribute
this to the early survival advantage of GalNAc-T6 expression
mentioned above.
Interestingly, we found that positive GalNAc-T6 expression was
closely associated with GalNAc-T3 positivity (P¼0.002, r¼0.356)
in our cohort. We used the anti-human polyclonal GalNAc-T6
antibody raised against a completely distinctive synthetic peptide
(GFYTPAELKPFWERPPQDP) from GYYTAAELKPVLDRPPQDS
of GalNAc-T3 for both immunohistochemistry and western
blotting (Nomoto et al, 1999). The results revealed GalNAc-T6-
or GalNAc-T3-specific staining in clinical specimens (Figurse 2A
and B) and a distinct specific band of GalNAc-T6 (Figure 4) or
GalNAc-T3 (data not shown) detected in the cytoplasmic fraction
of pancreatic cancer cell lines, respectively. Additionally, the
preliminary immunohistochemical examinations of different kinds
of adenocarcinomas demonstrated ubiquitous expression of
GalNAc-T3 in most specimens of lung, breast, gastric, and colon
cancers, whereas GalNAc-T6 was expressed in only a few cases of
them. All these confirmed the specificity of our GalNAc-T3 and -T6
antibodies.
Indeed, among all the isoforms, GalNAc-T6 and -T3 formed a
subfamily with high sequence similarity in the coding region and
shared similar kinetic properties and acceptor substrate specifi-
cities which are distinct from the other GalNAc-Ts (Bennett et al,
1999). It has been reported that there are at least two kinds of
interaction – competition or complement – among the isoforms of
GalNAc-Ts, as proven by experiments in vitro (Brockhausen et al,
1990; Bennett et al, 1998). Thus, the interaction of GalNAc-T6 and
-T3 is a prospective topic awaiting illumination. At first, we
hypothesised that the survival duration might be different between
the double negative group and either positive group if the
relationship between GalNAc-T3 and -T6 were complementary.
On the other hand, if GalNAc-T3 and -T6 competed with each
other, there might be some differences in the survival duration
between the GalNAc-T3 positive-only group and the GalNAc-T6
positive-only group. Hence, the cohort was divided into two such
manners (double negative vs either positive, and GalNAc-T3
positive-only vs GalNAc-T6 positive-only) and the Kaplan–Meier
method was used to verify them. Unexpectedly, the overall survival
of patients showed no significant difference (P¼0.618 and 0.451,
respectively) in either classification approach, suggesting that
there was no apparent competitive or complementary correlation
between GalNAc-T3 and -T6. Based on our analysis with a small
cohort, GalNAc-T3 and -T6 expressed together, but might function
separately, which was very interesting and needs further con-
firmation in larger cohorts later.
In summary, the present findings demonstrate that the positive
expression of GalNAc-T6 in pancreatic cancer has a significantly
close relationship with the well to moderately histopathologic
phenotype, absence of VI, and high incidence of early stage of the
AJCC system, namely well-differentiated and non-invasive charac-
teristics. Moreover, the outcome of the patients who had tumours
with positive GalNAc-T6 expression is significantly better than that
with negative GalNAc-T6 expression, especially in the early period
after surgery. On the other hand, most GalNAc-T6-positive cases
expressed GalNAc-T3 as well, whereas they influenced overall
survival separately. Based on these features, we can, for the first
time, implicate that GalNAc-T6 is an independent novel and useful
marker of prognosis in patients with pancreatic cancer, but
GalNAc-T3 is not. Compared with more conventional markers
like CA19-9, CEA, or mucins, GalNAc-T6 is suggested to have a
potential but special advantage to predict not only the prognosis of
patients, but local aggression and metastasis too. It is of clinical
value to identify the danger of local invasion and metastasis, which
are the primary causes of the poor outcome for this cancer. By
contrast, we admit the disadvantage of this molecular marker. Its
negative expression in undifferentiated cancer makes it difficult to
be used as a diagnostic marker in pancreatic cancer. However, it
might be a candidate for combination with the conventional
markers mentioned above.
Actually, since this cohort was not big, margin status did not
predict the ultimate outcomes in the univariate analysis. It is
expected that the status and the prognostic value of GalNAc-T6
will be evaluated in a larger cohort. On the other hand, it is
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spostulated that GalNAc-T6 had a key role in various types
of cancer, thus evaluation of its prognostic value in other
cancer types would be another important and intriguing topic.
Furthermore, it is worth doing more molecular experiments on
the potential invasive and metastatic suppressor function of
GalNAc-T6 in pancreatic cancer. Finally, we plan to perform
a high-throughput assay to evaluate the functions of other
GalNAc-Ts in pancreatic cancers. It would be very interesting to
further study the relationships between GalNAc-Ts and mucins.
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